Patents by Inventor Philip Janiak

Philip Janiak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190359729
    Abstract: The invention provides antibodies that specifically bind to Plasminogen Activator inhibitor type-1 (PAI-1). The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-PAI-1 antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies to modulate PAT-1 activity or detect PAI-1, either in vitro or in vivo, are also provided. The disclosure further provides methods of making antibodies that specifically bind to PAT-1 in the active conformational state.
    Type: Application
    Filed: August 6, 2019
    Publication date: November 28, 2019
    Inventors: Alla Pritsker, Patrick Grailhe, Alexey Rak, Magali Mathieu, Christopher Ryan Morgan, Nicolas Baurin, Bruno Poirier, Cyril Daveu, Francis Duffieux, Han Li, Dorothea Kominos, Philip Janiak
  • Publication number: 20180155444
    Abstract: The invention provides antibodies that specifically bind to Plasminogen Activator Inhibitor type-1 (PAI-1). The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-PAI-1 antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies to modulate PAI-1 activity or detect PAI-1, either in vitro or in vivo, are also provided. The disclosure further provides methods of making antibodies that specifically bind to PAI-1 in the active conformational state.
    Type: Application
    Filed: November 10, 2017
    Publication date: June 7, 2018
    Inventors: Alla Pritsker, Patrick Grailhe, Alexey Rak, Magali Mathieu, Christopher Ryan Morgan, Nicolas Baurin, Bruno Poirier, Cyril Daveu, Francis Duffieux, Han Li, Dorothea Kominos, Philip Janiak
  • Patent number: 9845363
    Abstract: The invention provides antibodies that specifically bind to Plasminogen Activator Inhibitor type-1 (PAI-1), The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-PAI-1 antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies to modulate PAI-1 activity or detect PAI-1, either in vitro or in vivo, are also provided. The disclosure further provides methods of making antibodies that specifically bind to PAI-1 in the active conformational state.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: December 19, 2017
    Assignee: Sanofi
    Inventors: Alla Pritsker, Patrick Grailhe, Alexey Rak, Magali Mathieu, Christopher Ryan Morgan, Nicolas Baurin, Bruno Poirier, Cyril Daveu, Francis Duffieux, Han Li, Dorothea Kominos, Philip Janiak
  • Patent number: 9782411
    Abstract: {4-[5-(3-chloro-phenoxy)-oxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid or a pharmaceutically acceptable salt thereof for use in the prevention or treatment of AKI (acute kidney injury). Medicament and pharmaceutical composition thereof.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: October 10, 2017
    Assignee: SANOFI
    Inventors: Véronique Briand, Sabine Gratzer, Thomas Huebschle, Philip Janiak, Dieter Kadereit, Ashfaq Parkar, Bruno Poirier, Matthias Schaefer, Paulus Wohlfart
  • Publication number: 20160235756
    Abstract: {4-[5-(3-chloro-phenoxy)-oxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid or a pharmaceutically acceptable salt thereof for use in the prevention or treatment of AKI (acute kidney injury). Medicament and pharmaceutical composition thereof.
    Type: Application
    Filed: October 15, 2014
    Publication date: August 18, 2016
    Applicant: Sanofi
    Inventors: Véronique BRIAND, Sabine GRATZER, Thomas HUEBSCHLE, Philip JANIAK, Dieter KADEREIT, Ashfaq PARKAR, Bruno POIRIER, Matthias SCHAEFER, Paulus WOHLFART
  • Publication number: 20160200831
    Abstract: The invention provides antibodies that specifically bind to Plasminogen Activator Inhibitor type-1 (PAI-1), The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-PAI-1 antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies to modulate PAI-1 activity or detect PAI-1, either in vitro or in vivo, are also provided. The disclosure further provides methods of making antibodies that specifically bind to PAI-1 in the active conformational state.
    Type: Application
    Filed: August 13, 2014
    Publication date: July 14, 2016
    Inventors: Alla Pritsker, Patrick Grailhe, Alexey Rak, Magali Mathieu, Christopher Ryan Morgan, Nicolas Baurin, Bruno Poirer, Cyril Daveu, Francis Duffieux, Han Li, Dorothea Kominos, Philip Janiak
  • Patent number: 8846654
    Abstract: A subject-matter of the present invention is the use of compounds of formula (I) in the base, hydrate or solvate form or in the form of their mixtures, as medicaments or for the preparation of medicaments intended for the treatment of at least one cardiovascular disease and/or to prevent the appearance of at least one cardiovascular disease.
    Type: Grant
    Filed: October 7, 2011
    Date of Patent: September 30, 2014
    Assignee: Sanofi
    Inventors: Philip Janiak, Gilbert Marciniak, Jean-Francois Nave, Fabrice Viviani
  • Patent number: 8552201
    Abstract: The present invention relates to derivatives of 5,6-bisaryl-2-pyridine-carboxamide, their preparation and their application in therapeutics as antagonists of urotensin II receptors.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: October 8, 2013
    Assignee: Sanofi
    Inventors: Jean-Michel Altenburger, Valérie Fossey, Philip Janiak, Gilbert Lassalle, Frédéric Petit, Jean Claude Vernieres
  • Publication number: 20120184522
    Abstract: A subject-matter of the present invention is the use of compounds of formula (I) in the base, hydrate or solvate form or in the form of their mixtures, as medicaments or for the preparation of medicaments intended for the treatment of at least one cardiovascular disease and/or to prevent the appearance of at least one cardiovascular disease.
    Type: Application
    Filed: October 7, 2011
    Publication date: July 19, 2012
    Applicant: SANOFI
    Inventors: Philip JANIAK, Gilbert MARCINIAK, Jean-Francois NAVE, Fabrice VIVIANI
  • Publication number: 20120108611
    Abstract: The present invention relates to derivatives of 5,6-bisaryl-2-pyridine-carboxamide, their preparation and their application in therapeutics as antagonists of urotensin II receptors.
    Type: Application
    Filed: December 29, 2011
    Publication date: May 3, 2012
    Inventors: Jean-Michel Altenburger, Valérie Fossey, Gilbert Lassalie, Frédéric Petit, Jean Claude Vernieres, Philip Janiak
  • Patent number: 8110579
    Abstract: The present invention relates to derivatives of 5,6-bisaryl-2-pyridine-carboxamide, their preparation and their application in therapeutics as antagonists of urotensin II receptors.
    Type: Grant
    Filed: February 11, 2009
    Date of Patent: February 7, 2012
    Assignee: Sanofi-Aventis
    Inventors: Jean-Michel Altenburger, Valerie Fossey, Philip Janiak, Gilbert Lassalle, Frederic Petit, Jean Claude Vernieres
  • Publication number: 20090318473
    Abstract: The present invention relates to derivatives of 5,6-bisaryl-2-pyridine-carboxamide, their preparation and their application in therapeutics as antagonists of urotensin II receptors.
    Type: Application
    Filed: February 11, 2009
    Publication date: December 24, 2009
    Inventors: Jean-Michel Altenburger, Valerie Fossey, Gilbert Lassalle, Frederic Petit, Jean Claude Vernieres, Philip Janiak
  • Patent number: 7622488
    Abstract: This invention relates to use of a pyrazole-derived compound that is an antagonist of cannabinoid CB1 receptors, alone or in combination with another active ingredient, for preparing medicinal products that are of use in the prevention and treatment of kidney diseases.
    Type: Grant
    Filed: August 2, 2007
    Date of Patent: November 24, 2009
    Assignee: sanofi-aventis
    Inventors: Mohammed Bensaid, Jean-Marc Herbert, Philip Janiak
  • Publication number: 20090215755
    Abstract: Use of a pyrazole-derived compound that is an antagonist for cannabinoid CB1 receptors, alone or combined with another active principal, for preparing medicinal products that are useful in the prevention and treatment of dyslipidemias and of diseases related to dyslipidemias and/or to obesity, such as metabolic syndrome, cardiovascular risks and hepatic diseases.
    Type: Application
    Filed: May 11, 2009
    Publication date: August 27, 2009
    Applicant: SANOFI-AVENTIS
    Inventors: Michele Arnone, Jean Marc Herbert, Hassan Massoud Heshmati, Philip Janiak, Mohammed Bensaid
  • Publication number: 20080015228
    Abstract: This invention relates to use of a pyrazole-derived compound that is an antagonist of cannabinoid CB1 receptors, alone or in combination with another active ingredient, for preparing medicinal products that are of use in the prevention and treatment of kidney diseases.
    Type: Application
    Filed: August 2, 2007
    Publication date: January 17, 2008
    Applicant: SANOFI-AVENTIS
    Inventors: Mohammed BENSAID, Jean Marc HERBERT, Philip JANIAK
  • Publication number: 20070072907
    Abstract: Use of a pyrazole-derived compound that is an antagonist for cannabinoid CB1 receptors, alone or combined with another active principal, for preparing medicinal products that are useful in the prevention and treatment of dyslipidaemias and of diseases related to dyslipidaemias and/or to obesity, such as metabolic syndrome, cardiovascular risks and hepatic diseases.
    Type: Application
    Filed: April 24, 2006
    Publication date: March 29, 2007
    Applicant: sanofi-aventis
    Inventors: Michele Arnone, Jean Marc Herbert, Hassan Heshmati, Philip Janiak, Mohammed Bensaid
  • Patent number: 5569647
    Abstract: The invention relates to a compound selected from those of formula (I) (SEQ ID NO:1): ##STR1## in which R.sub.1, R.sub.2, X.sub.1 and X.sub.2 are as defined in the description, useful as inhibitor of the proliferation component of vascular smooth muscle cells.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 29, 1996
    Assignee: Adir et Compagnie
    Inventors: Jean-Luc Fauchere, Christophe Thurieau, Jean-Paul Vilaine, Philip Janiak
  • Patent number: 5298503
    Abstract: Compounds of formula (I): ##STR1## wherein R.sub.1, R.sub.2, U, X, Y, Z, n, m, p and r are as defined in the description, and medicaments containing the same.
    Type: Grant
    Filed: July 30, 1992
    Date of Patent: March 29, 1994
    Assignee: Adir et Compagnie
    Inventors: Jean-Louis Peglion, Jean-Paul Vilaine, Nicole Villeneuve, Philip Janiak
  • Patent number: 5296482
    Abstract: The compounds are 3-[ (benzocycloalkyl)alkyl amino alkyl] -1,3,4,5-te trahydro 2H- 3-benzazepin-2 ones useful in cardiovascular field.A compound disclosed is (R,S)-7,8-dimethoxy-3-{3-{N-[(4,5-dimethoxybenzocyclobut-1-yl) methyl]-N-methyl amino}propyl}-1,3,4,5-tetrahydro-2H-3-benzazepin-2-one.
    Type: Grant
    Filed: September 25, 1992
    Date of Patent: March 22, 1994
    Assignee: Adir et Compagnie
    Inventors: Jean-Louis Peglion, Joel Vian, Jean-Paul Vilaine, Nicole Villeneuve, Philip Janiak, Jean-Pierre Bidouard
  • Patent number: 5208243
    Abstract: Compounds of formula (I): ##STR1## with R.sub.1, R.sub.2, U, X, Y, Z, n, m, p and r as defined in the description.Medicinal products.
    Type: Grant
    Filed: July 30, 1992
    Date of Patent: May 4, 1993
    Assignee: Adir et Compagnie
    Inventors: Jean-Louis Peglion, Jean-Paul Vilaine, Nicole Villeneuve, Philip Janiak